A. Sinclair Dunlop - 14 Dec 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Director
Signature
/s/ David Watson, attorney-in-fact for Sinclair Dunlop
Issuer symbol
APLS
Transactions as of
14 Dec 2023
Net transactions value
+$82,754
Form type
4
Filing time
15 Dec 2023, 16:04:49 UTC
Previous filing
05 Dec 2023
Next filing
02 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $82,754 +6,274 +5.1% $13.19 128,677 14 Dec 2023 Direct
holding APLS Common Stock 192,679 14 Dec 2023 Indirect Owner (Epidarex) F1
holding APLS Common Stock 31,855 14 Dec 2023 Indirect Owner (Masa) F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -6,274 -47% $0.000000 7,000 14 Dec 2023 Common Stock 6,274 $13.19 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are held by Epidarex and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.
F2 The securities are held by MASA and the reporting person, a managing partner of MASA, may be deemed to have voting and dispositive power over the shares held by MASA. The reporting person disclaims beneficial ownership over the shares held by MASA except to the extent of his pecuniary interest therein.
F3 This option was granted on January 1, 2019 and fully vested.